Earth Science Tech, Inc. (OTC: ETST) announced financial and operational results for the third fiscal quarter ended December 31, 2025, highlighting significant year-over-year growth. The company reported revenue of $8.4 million, a 14.1% increase from the prior-year period, driven by continued expansion across its operating segments. Gross profit reached $6.4 million, reflecting an impressive 76.3% margin, while net income surged 341% to $910,000. Adjusted EBITDA totaled $1.2 million, underscoring improved operational efficiency.
The company's balance sheet strengthened during the quarter, with total assets increasing to $8.1 million. Earth Science Tech ended the period with $416,000 in cash, $773,000 in working capital, and no bank debt. Management attributed the strong performance to operating leverage and ongoing expansion initiatives heading into calendar 2026. Additionally, the company repurchased and retired 3.7 million shares during the first nine months of fiscal 2026, demonstrating a commitment to shareholder value.
Earth Science Tech operates as a strategic holding company focused on value creation through acquisition, operational optimization, and management of its operating businesses. Its current operations include compounding pharmaceuticals, telemedicine, and real estate development through wholly owned subsidiaries such as RxCompoundStore.com, LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC, and Earth Science Foundation, Inc., among others. The company also holds an 80% interest in MagneChef.
For more details on the full press release, visit https://ibn.fm/emIBm. The latest news and updates relating to ETST are available in the company's newsroom at https://ibn.fm/ETST.
The results underscore Earth Science Tech's ability to generate substantial profit growth from modest revenue gains, a sign of effective cost management and scalable operations. With no bank debt and a solid working capital position, the company appears well-positioned to pursue further strategic initiatives. The share repurchase program also signals management's confidence in the company's valuation and future prospects.
These developments are particularly noteworthy given the challenging macroeconomic environment, as many small-cap companies struggle with margin compression. Earth Science Tech's 76.3% gross margin and 341% net income growth suggest that its diversified business model—spanning pharmaceuticals, telemedicine, and real estate—is providing resilience and upside.
